elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q38694128-0ACF5642-2D27-4F0A-A3AB-6F9A392DCC8D
Q38694128-0ACF5642-2D27-4F0A-A3AB-6F9A392DCC8D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38694128-0ACF5642-2D27-4F0A-A3AB-6F9A392DCC8D
BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model
P2860
Q38694128-0ACF5642-2D27-4F0A-A3AB-6F9A392DCC8D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38694128-0ACF5642-2D27-4F0A-A3AB-6F9A392DCC8D
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f18deeb676d53b4c8a316fce8b7dd956beb3d7be
P2860
Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX).